Roth Capital Estimates biote's Q4 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMD - Free Report) - Stock analysts at Roth Capital dropped their Q4 2024 EPS estimates for biote in a research report issued on Wednesday, November 13th. Roth Capital analyst G. Kelly now forecasts that the company will post earnings per share of $0.13 for the quarter, down from their previous estimate of $0.19. The consensus estimate for biote's current full-year earnings is $0.53 per share. Roth Capital also issued estimates for biote's Q1 2025 earnings at $0.13 EPS, Q2 2025 earnings at $0.16 EPS, Q3 2025 earnings at $0.18 EPS, Q4 2025 earnings at $0.20 EPS and FY2025 earnings at $0.67 EPS.

biote Stock Performance

NASDAQ:BTMD traded down $0.15 during mid-day trading on Thursday, hitting $6.57. The stock had a trading volume of 231,776 shares, compared to its average volume of 163,573. biote has a twelve month low of $3.65 and a twelve month high of $8.44. The stock has a market cap of $356.23 million, a price-to-earnings ratio of 25.85 and a beta of 0.94. The company's 50 day simple moving average is $5.53 and its 200 day simple moving average is $6.28.

Institutional Trading of biote

A number of hedge funds have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its position in shares of biote by 1,016.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 660,069 shares of the company's stock valued at $4,931,000 after buying an additional 600,956 shares in the last quarter. Renaissance Technologies LLC raised its position in biote by 251.8% during the second quarter. Renaissance Technologies LLC now owns 193,077 shares of the company's stock valued at $1,442,000 after purchasing an additional 138,200 shares in the last quarter. Sanders Morris Harris LLC lifted its stake in biote by 131.2% during the third quarter. Sanders Morris Harris LLC now owns 180,965 shares of the company's stock worth $1,010,000 after purchasing an additional 102,706 shares during the last quarter. GDS Wealth Management acquired a new stake in shares of biote in the 2nd quarter valued at $432,000. Finally, Skylands Capital LLC raised its holdings in shares of biote by 36.2% during the 2nd quarter. Skylands Capital LLC now owns 160,845 shares of the company's stock worth $1,202,000 after buying an additional 42,729 shares in the last quarter. 21.68% of the stock is owned by institutional investors and hedge funds.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.